"Based on the unmet need and severity of Prader-Willi syndrome and learnings from our initial study, we plan to initiate an ...

Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...

Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

BOSTON - Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a $3.4 billion biopharmaceutical company specializing in rare neuroendocrine diseases, has reclaimed the rights to its obesity drug, IMCIVREE ...

Rhythm’s lead asset, IMCIVREE ® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess ...

BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living ...

BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living ...

BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...